All entries for: Aegle Therapeutics

Aegle Therapeutics received funding to advance AGLE-102 for the treatment of dystrophic epidermolysis bullosa (DEB), a rare disease.

City: Woburn
State: MA
Investment Amount(In Millions): $4.56